At the moment, DADA2 treatment may differ based on clinical phenotype: most inflammatory features can be effectively controlled using TNF inhibitors, with reduction of stroke recurrence (18, 87, 88), improvement of blood vessels endothelial integrity and resolution of inflammatory myeloid cell infiltrates (37). The gene discussed is TNF; the disease is Stroke.